Trevena (TRVN) Competitors $0.0012 -0.27 (-99.56%) As of 08/28/2025 11:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. NMTR, PTPI, BPTH, PBLA, BPTSY, HEPA, WINT, SMFL, VINC, and BONShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Bio-Path (BPTH), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Windtree Therapeutics (WINT), Smart for Life (SMFL), Vincerx Pharma (VINC), and Bon Natural Life (BON). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors 9 Meters Biopharma Petros Pharmaceuticals Bio-Path Panbela Therapeutics Biophytis Hepion Pharmaceuticals Windtree Therapeutics Smart for Life Vincerx Pharma Bon Natural Life Trevena (NASDAQ:TRVN) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Do institutionals and insiders have more ownership in TRVN or NMTR? 13.6% of Trevena shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, TRVN or NMTR? Trevena has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Does the media refer more to TRVN or NMTR? In the previous week, Trevena's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment Trevena Neutral 9 Meters Biopharma Neutral Is TRVN or NMTR more profitable? Trevena's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% 9 Meters Biopharma N/A -584.97%-159.45% Do analysts rate TRVN or NMTR? Trevena currently has a consensus target price of $5.00, suggesting a potential upside of 416,566.67%. Given Trevena's stronger consensus rating and higher probable upside, equities research analysts clearly believe Trevena is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.009 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, TRVN or NMTR? Trevena has higher revenue and earnings than 9 Meters Biopharma. Trevena is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K0.00-$40.29M-$47.040.009 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A SummaryTrevena beats 9 Meters Biopharma on 8 of the 11 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$848.51M$5.78B$9.79BDividend YieldN/A4.84%3.95%4.02%P/E Ratio0.001.1331.2426.59Price / Sales0.0026.55429.49156.00Price / CashN/A19.5637.7359.36Price / Book0.006.7310.366.68Net Income-$40.29M-$4.20M$3.27B$265.59M7 Day PerformanceN/A16.11%1.40%0.62%1 Month PerformanceN/A17.10%6.21%2.61%1 Year PerformanceN/A34.92%46.60%22.34% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.261 of 5 stars$0.00-99.6%$5.00+416,566.7%-100.0%$1K$443K0.0040Gap DownHigh Trading VolumeNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020PTPIPetros PharmaceuticalsN/A$0.03-6.5%N/A-99.7%$904K$5.11M-0.0120BPTHBio-Path0.8186 of 5 stars$0.10+1.0%N/A-87.1%$839KN/A0.0010Positive NewsAnalyst UpgradePBLAPanbela Therapeutics0.2762 of 5 stars$0.16flatN/A-56.5%$767KN/A0.006Positive NewsBPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030Positive NewsGap UpHEPAHepion Pharmaceuticals0.4957 of 5 stars$0.06+3.6%N/A-99.8%$686KN/A-0.0120Gap DownWINTWindtree Therapeutics2.2916 of 5 stars$0.11-6.4%$350.00+309,634.5%-100.0%$414KN/A0.0030SMFLSmart for LifeN/A$0.04+1,242.4%N/A-99.9%$314K$11.11M0.00110Gap UpVINCVincerx Pharma2.5234 of 5 stars$0.06+33.3%$40.00+66,566.7%-99.7%$314KN/A0.0060Gap UpBONBon Natural LifeN/A$1.39-0.7%N/AN/A$232K$23.84M0.00100Gap Down Related Companies and Tools Related Companies NMTR Alternatives PTPI Alternatives BPTH Alternatives PBLA Alternatives BPTSY Alternatives HEPA Alternatives WINT Alternatives SMFL Alternatives VINC Alternatives BON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access